Global Biosimilars Market by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Indication (Autoimmune Diseases, Blood Disorders, Chronic Diseases), Manufacturing - Forecast 2024-2030- Product Image

Sale

Global Biosimilars Market by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Indication (Autoimmune Diseases, Blood Disorders, Chronic Diseases), Manufacturing - Forecast 2024-2030

Report
195 Pages
March 2024
Region: Global
360iResearch™
ID: 4807823

UP TO €846EUR$875USD£727GBP OFF until Dec 31^st 2024

The Biosimilars Market size was estimated at USD 40.70 billion in 2023, USD 49.91 billion in 2024, and is expected to grow at a CAGR of 23.31% to reach USD 176.48 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Biosimilars Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biosimilars Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Biosimilars Market, highlighting leading vendors and their innovative profiles. These include Alvotech, Amgen Inc., Apotex Inc., Biocon Limited, BioFactura, Inc., Biogen Inc., Boehringer Ingelheim International GmbH., Catalent, Inc, Celltrion Healthcare Co.,Ltd., Coherus BioSciences, Dr. Reddy's Laboratories Limited, Eden Biologics, Inc., F. Hoffmann-La Roche AG, Fresenius Kabi, Innovent Biologics, Inc., Intas Pharmaceuticals Ltd., Kashiv BioSciences, LLC., Merck & Co., Inc., NeuClone, Nippon Kayaku Co., Ltd., Novartis AG, Panacea Biotec Limited, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific, Inc.

Market Segmentation & Coverage

This research report categorizes the Biosimilars Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Recombinant Glycosylated Proteins
  - Erythropoietin
  - Follitropin
  - Monoclonal Antibodies
    - Adalimumab
    - Infliximab
    - Rituximab
- Recombinant Non-Glycosylated Proteins
  - Granulocyte Colony-Stimulating Factor
  - Insulin
  - Interferons
    - Interferon-Alpha
    - Interferon-Beta
  - Recombinant Human Growth Hormone
- Recombinant Peptides
  - Calcitonin
  - Glucagon
Indication
- Autoimmune Diseases
- Blood Disorders
- Chronic Diseases
- Growth Hormone Deficiency
- Infectious Diseases
- Oncology
Manufacturing
- Contract Manufacturing
- In-House Manufacturing

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Biosimilars Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biosimilars Market?
What are the technology trends and regulatory frameworks in the Biosimilars Market?
What is the market share of the leading vendors in the Biosimilars Market?
Which modes and strategic moves are suitable for entering the Biosimilars Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Biosimilars Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising healthcare expenditure into the pharmaceutical industry
5.1.1.2. Increasing demand for lower cost biosimilars drugs than original biologics
5.1.2. Restraints
5.1.2.1. Reluctance of physicians to prescribe biosimilars
5.1.3. Opportunities
5.1.3.1. Improvements in biosimilar production processes
5.1.3.2. Supportive government initiative to develop biosimilars
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements and laws
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Biosimilars Market, by Product

6.1. Introduction
6.2. Recombinant Glycosylated Proteins
6.3.1. Erythropoietin
6.3.2. Follitropin
6.3.3. Monoclonal Antibodies
6.3.4.1. Adalimumab
6.3.4.2. Infliximab
6.3.4.3. Rituximab
6.3. Recombinant Non-Glycosylated Proteins
6.4.1. Granulocyte Colony-Stimulating Factor
6.4.2. Insulin
6.4.3. Interferons
6.4.4.1. Interferon-Alpha
6.4.4.2. Interferon-Beta
6.4.4. Recombinant Human Growth Hormone
6.4. Recombinant Peptides
6.5.1. Calcitonin
6.5.2. Glucagon

7. Biosimilars Market, by Indication

7.1. Introduction
7.2. Autoimmune Diseases
7.3. Blood Disorders
7.4. Chronic Diseases
7.5. Growth Hormone Deficiency
7.6. Infectious Diseases
7.7. Oncology

8. Biosimilars Market, by Manufacturing

8.1. Introduction
8.2. Contract Manufacturing
8.3. In-House Manufacturing

9. Americas Biosimilars Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Biosimilars Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Biosimilars Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Alvotech
13.1.2. Amgen Inc.
13.1.3. Apotex Inc.
13.1.4. Biocon Limited
13.1.5. BioFactura, Inc.
13.1.6. Biogen Inc.
13.1.7. Boehringer Ingelheim International GmbH.
13.1.8. Catalent, Inc
13.1.9. Celltrion Healthcare Co.,Ltd.
13.1.10. Coherus BioSciences
13.1.11. Dr. Reddy's Laboratories Limited
13.1.12. Eden Biologics, Inc.
13.1.13. F. Hoffmann-La Roche AG
13.1.14. Fresenius Kabi
13.1.15. Innovent Biologics, Inc.
13.1.16. Intas Pharmaceuticals Ltd.
13.1.17. Kashiv BioSciences, LLC.
13.1.18. Merck & Co., Inc.
13.1.19. NeuClone
13.1.20. Nippon Kayaku Co., Ltd.
13.1.21. Novartis AG
13.1.22. Panacea Biotec Limited
13.1.23. Pfizer Inc.
13.1.24. Samsung Bioepis Co., Ltd.
13.1.25. Sanofi S.A.
13.1.26. Shanghai Henlius Biotech, Inc.
13.1.27. Teva Pharmaceutical Industries Ltd.
13.1.28. Thermo Fisher Scientific, Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. BIOSIMILARS MARKET RESEARCH PROCESS
FIGURE 2. BIOSIMILARS MARKET SIZE, 2023 VS 2030
FIGURE 3. BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BIOSIMILARS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. BIOSIMILARS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BIOSIMILARS MARKET DYNAMICS
FIGURE 7. BIOSIMILARS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. BIOSIMILARS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. BIOSIMILARS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. BIOSIMILARS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2023 VS 2030 (%)
FIGURE 12. BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. BIOSIMILARS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 8. BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 12. BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 17. BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 21. BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 26. BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 36. BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 63. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 64. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 65. CANADA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 66. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 67. CANADA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 68. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 69. CANADA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. CANADA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 71. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 72. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 74. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 75. MEXICO BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 77. MEXICO BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. MEXICO BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 105. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 106. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 107. CHINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 108. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 109. CHINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 110. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 111. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 113. INDIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 114. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 115. INDIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 116. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 117. INDIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 118. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 119. INDIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. INDIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 121. INDONESIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 122. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 126. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 127. INDONESIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. INDONESIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 129. JAPAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 130. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 131. JAPAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 132. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 133. JAPAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 134. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 135. JAPAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. JAPAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 137. MALAYSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 138. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 142. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 143. MALAYSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. MALAYSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 145. PHILIPPINES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 146. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 150. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 151. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 152. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 153. SINGAPORE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 154. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 158. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 159. SINGAPORE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. SINGAPORE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 166. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 167. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 169. TAIWAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 170. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 174. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 175. TAIWAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. TAIWAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 177. THAILAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 178. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 179. THAILAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 180. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 181. THAILAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 182. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 183. THAILAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. THAILAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 185. VIETNAM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 186. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 190. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 191. VIETNAM BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. VIETNAM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 202. DENMARK BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 203. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 204. DENMARK BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 205. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 206. DENMARK BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 207. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 208. DENMARK BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 209. DENMARK BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 210. EGYPT BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 211. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 212. EGYPT BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 213. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 214. EGYPT BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 215. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 216. EGYPT BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 217. EGYPT BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 218. FINLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 219. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 220. FINLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 221. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 222. FINLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 224. FINLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. FINLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 226. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 227. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 228. FRANCE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 229. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 230. FRANCE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 231. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 232. FRANCE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 233. FRANCE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 234. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 235. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 236. GERMANY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 237. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 238. GERMANY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 239. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 240. GERMANY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 241. GERMANY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 249. ISRAEL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 250. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 251. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 252. ITALY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 253. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 254. ITALY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 255. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 256. ITALY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 257. ITALY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 274. NORWAY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 275. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 276. NORWAY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 277. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 278. NORWAY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 279. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 280. NORWAY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 281. NORWAY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 282. POLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 283. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 284. POLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 285. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 286. POLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 287. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 288. POLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 289. POLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 290. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 291. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 292. QATAR BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 293. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 294. QATAR BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 295. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 296. QATAR BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 297. QATAR BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 298. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 299. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 320. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 322. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 323. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 324. SPAIN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 325. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 326. SPAIN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 327. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 328. SPAIN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 329. SPAIN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 330. SWEDEN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 331. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 332. SWEDEN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 333. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 334. SWEDEN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 335. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 336. SWEDEN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 337. SWEDEN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 338. SWITZERLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 339. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 340. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 341. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 342. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 343. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 344. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 345. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 346. TURKEY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 347. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 348. TURKEY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 349. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 350. TURKEY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 351. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 352. TURKEY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 353. TURKEY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 354. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 355. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030

Companies Mentioned

Alvotech
Amgen Inc.
Apotex Inc.
Biocon Limited
BioFactura, Inc.
Biogen Inc.
Boehringer Ingelheim International GmbH.
Catalent, Inc
Celltrion Healthcare Co.,Ltd.
Coherus BioSciences
Dr. Reddy's Laboratories Limited
Eden Biologics, Inc.
F. Hoffmann-La Roche AG
Fresenius Kabi
Innovent Biologics, Inc.
Intas Pharmaceuticals Ltd.
Kashiv BioSciences, LLC.
Merck & Co., Inc.
NeuClone
Nippon Kayaku Co., Ltd.
Novartis AG
Panacea Biotec Limited
Pfizer Inc.
Samsung Bioepis Co., Ltd.
Sanofi S.A.
Shanghai Henlius Biotech, Inc.
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	195
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 49.91 Billion
Forecasted Market Value ( USD ) by 2030	$ 176.48 Billion
Compound Annual Growth Rate	23.3%
Regions Covered	Global
No. of Companies Mentioned	28

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3262EUR$3,374USD£2,802GBP €3624EUR$3,749USD£3,113GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4132EUR$4,274USD£3,549GBP €4591EUR$4,749USD£3,944GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5002EUR$5,174USD£4,297GBP €5558EUR$5,749USD£4,774GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5872EUR$6,074USD£5,044GBP €6525EUR$6,749USD£5,605GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7613EUR$7,874USD£6,539GBP €8458EUR$8,749USD£7,265GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Biosimilars: Global Strategic Business Report

Biosimilars Market Size, Share & Trends Analysis By Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins), By Application (Rheumatoid Arthritis, Oncology), By Region And Segment Forecasts 2023 - 2030

Biosimilars Market by Material Type (Silicon, Germanium, Transition Metal Oxides, Gold), Industry (Consumer Electronics, Automotive, Aviation, Energy, Medical Devices), Regional Outlook - Global Forecast up to 2032

Global Biosimilars Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

Global Biosimilars Market Report and Forecast 2023-2031

About the Biosimilar Market